ABCDEFGHI
1Main
2BrandBAN2401
3Genericlecanemab
4MOAanti-AB protofibril antibody
5Clinical Trials
6Phase III "CLARITY" n=1906 early Alzheimer's - NCT03887455, full results at CTAD 11/29/22
7PE: CDR-SB at 18 months
810mg/kg q2w, 720mg subcutaneous qw1.66666666666666651.2166666666666666at 18 weeks - but what was baseline? 3.5 (donanemab) or 6.7 (donepezil)
9File for approval by 3/31/23.1.42/year in Aricept
10-0.45 p=0.00005 at 18 months ("Lecanemab treatment met the primary endpoint and reduced clinical decline on the global cognitive and functional scale, CDR-SB, compared with placebo at 18 months by 27%, which represents a treatment difference in the score change of -0.45 (p=0.00005) in the analysis of Intent-to-treat (ITT) population.")
11
12Phase III "AHEAD 3-45" n=1400 - NCT04468659
13PACC5 PE at 4 years(!!)
14
15
16Phase II "Study 201"